CN111588725B - New application of compound ARV-825 in preparation of drug for preventing or treating African swine fever - Google Patents
New application of compound ARV-825 in preparation of drug for preventing or treating African swine fever Download PDFInfo
- Publication number
- CN111588725B CN111588725B CN202010684043.1A CN202010684043A CN111588725B CN 111588725 B CN111588725 B CN 111588725B CN 202010684043 A CN202010684043 A CN 202010684043A CN 111588725 B CN111588725 B CN 111588725B
- Authority
- CN
- China
- Prior art keywords
- arv
- compound
- swine fever
- african swine
- asfv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Abstract
The invention belongs to the technical field of African swine fever treatment, and particularly relates to a new application of a compound ARV-825 in preventing or treating African swine fever. The invention unexpectedly discovers that the compound ARV-825 can obviously inhibit RNA and protein expression levels of p30 and p72 in ASFV, prevent viruses from invading host cells and can be used for inhibiting the early infection of the ASFV; the compound ARV-825 can remarkably increase the expression levels of genes such as TNF-alpha, NF-kappa B, IL-1 beta, IL-8 and the like after ASFV infection, up-regulate the transcription levels of TNF-alpha, NF-kappa B, IL-1 beta and IL-8 and enhance immune response; therefore, the compound ARV-825 can be used for preventing or treating African swine fever.
Description
Technical Field
The invention belongs to the technical field of African swine fever treatment, and particularly relates to a new application of a compound ARV-825 in preventing or treating African swine fever.
Background
African Swine Fever (ASF) is an acute virulent infectious disease characterized by Fever of pigs and organ bleeding of the whole body of pigs caused by African Swine Fever Virus (ASFV), and the death rate of domestic pigs is as high as 100%. The disease first outbreaks in kenya 1921 and then is widely prevalent in domestic and wild pigs throughout africa. The 20 th century was introduced into europe in the 50 s, and the disease was cured for 40 years throughout europe. However, the disease was again introduced into grurgia from eastern africa in 2007, and then widely disseminated in eastern europe and introduced into elocusk, the far east russia, 2017. At the beginning of 8 months in 2019, a Hurongrong researcher reports the epidemic situation of the African swine in the first instance of China, and the disease spreads to 30 provinces and municipalities in China within a short time of one year, so that the disease continues to threaten the pig industry, wherein compared with 8 months in 2018, the yield of the domestic pig in 9 months in 2019 is reduced by 40%, the price of pork is doubled since 8 months in 2019, the yield is reduced by more than 40% in China, and the loss is serious. As no effective vaccine or specific therapeutic medicine exists so far, once the epidemic situation of the African swine fever occurs, the epidemic situation can be controlled only by a killing means, but the mode not only causes economic loss, but also cannot meet the requirement of large-scale pig raising in China. Therefore, how to effectively control the ASF epidemic situation is one of the great challenges facing the pig industry in the world at present, and is also a major strategic subject to be urgently solved by ASF prevention and control in China.
The p30 and p72 are key structural proteins in ASFV, and can neutralize virus after the virus attacks susceptible cells, and inhibit the attachment, replication and internalization processes of the virus. Wherein p30 is the main structural protein constituting the virus particle, and is also an important surface antigen, and is closely related to host cell tropism, pathogenicity and immunogenicity; p30 is expressed early in ASF infection, usually produced 2-4h post infection, and is expressed continuously throughout the infection, involved in virus internalization, and is involved in virus invasion into host cells. And p72 is a capsid protein, is the main structural protein of the African swine fever virus, can protect the virus nucleic acid from being damaged by nuclease or other physicochemical factors in the environment, is involved in the infection process of the virus and has good immunogenicity, the protein is generated in the late stage of virus infection, p72 is an important antigen protein of ASFV, is the main component of virus icosahedron, is important for the formation of virus capsid, and is involved in virus binding cells.
The compound ARV-825 can continuously reduce MYC level, and is mainly used for treating multiple cancers such as Triple Negative Breast Cancer (TNBC), Acute Myelogenous Leukemia (AML), NUT midline cancer, multiple myeloma, hematological malignancy and the like.
The invention unexpectedly discovers that the compound ARV-825 can obviously inhibit RNA and protein expression levels of p30 and p72 in ASFV, prevent viruses from invading host cells and can be used for inhibiting the early infection of the ASFV; the compound ARV-825 can remarkably increase the expression levels of genes such as TNF-alpha, NF-kappa B, IL-1 beta, IL-8 and the like after ASFV infection, up-regulate the transcription levels of TNF-alpha, NF-kappa B, IL-1 beta and IL-8 and enhance immune response; therefore, the compound ARV-825 can be used for preventing or treating African swine fever.
Disclosure of Invention
In view of the above technical problems, the present invention aims to provide an application of compound ARV-825 in preparing a drug for treating african swine fever, wherein the structural formula of the compound ARV-825 is shown as the following formula (i):
the invention also aims to provide application of a compound ARV-825 in preparing a medicament for preventing African swine fever, wherein the structural formula of the compound ARV-825 is shown as the following formula (I):
the invention also aims to provide an application of a compound ARV-825 in preparing a medicine for inhibiting transcription and expression of an African swine fever virus gene, wherein the structural formula of the compound ARV-825 is shown as the following formula (I):
the invention also aims to provide an application of a compound ARV-825 in preparing a medicament for inhibiting the expression of the p30RNA of African swine fever virus, wherein the structural formula of the compound ARV-825 is shown as the following formula (I):
the invention also aims to provide an application of a compound ARV-825 in preparing a medicament for inhibiting the expression of the p30 protein of the African swine fever virus, wherein the structural formula of the compound ARV-825 is shown as the following formula (I):
the invention also aims to provide an application of a compound ARV-825 in preparing a medicament for inhibiting the expression of the p72RNA of African swine fever virus, wherein the structural formula of the compound ARV-825 is shown as the following formula (I):
the invention also aims to provide an application of a compound ARV-825 in preparing a medicament for inhibiting the expression of the p72 protein of the African swine fever virus, wherein the structural formula of the compound ARV-825 is shown as the following formula (I):
another object of the present invention is to provide a use of compound ARV-825 for preparing a medicament for promoting the expression of inflammatory factors, wherein the compound ARV-825 has a structural formula shown in the following formula (I):
preferably, the inflammatory factors include TNF-alpha, NF-kappa B, IL-1 beta, IL-8.
Preferably, the compound ARV-825 is added with pharmaceutically acceptable carriers and/or auxiliary materials to be prepared into any one dosage form of tablets, sprays, granules, capsules, oral liquid, injections and suspensions.
The invention has the beneficial effects that: the invention unexpectedly discovers that the compound ARV-825 can obviously inhibit the RNA and protein expression level of p30 in ASFV, prevent viruses from invading host cells and can be used for inhibiting the early infection of the ASFV; the compound ARV-825 can remarkably increase the expression levels of genes such as TNF-alpha, NF-kappa B, IL-1 beta, IL-8 and the like after ASFV infection, up-regulate the transcription levels of TNF-alpha, NF-kappa B, IL-1 beta and IL-8 and enhance immune response; therefore, the compound ARV-825 can be used for preventing or treating African swine fever.
Drawings
FIG. 1 Compound ARV-825 inhibits African swine fever virus infection and replication;
FIG. 2 is a graph showing the results of the RNA expression levels of p30 and p 72;
FIG. 3 is a graph showing the results of the compound ARV-825 inhibiting the protein expression levels of p30 and p72 of African swine fever virus;
FIG. 4 is a graph showing the results of the up-regulation of host inflammation-related factor expression by ARV-825;
FIG. 5 is a graph showing the cytotoxicity results of ARV-825, a compound.
Detailed Description
In order to make the technical means, the creation characteristics, the achievement purposes and the effects of the invention easy to understand, the invention is further described with the specific embodiments. The scope of the invention is not limited to the examples described below.
The experiments described in the following examples obtain biosafety permits and african swine fever laboratory activity permits:
according to the related requirements of biosafety of a Lanzhou veterinary research institute of the Chinese agricultural academy of sciences, a biological safety 3-level laboratory (BSL-3) and related biological safety of African swine fever, the Lanzhou veterinary research institute biological safety committee, the laboratory animal ethics committee, the Chinese agricultural academy of sciences biological safety committee, the Lanzhou veterinary research institute experimental animal ethics committee and the Lanzhou veterinary research institute biological safety committee report step by step, the permission of developing highly pathogenic ASFV pathogens and animal research is obtained by the agricultural department, and the permission is recorded by the agricultural rural department and meets the requirements of national biological safety level.
Experimental cells, viral sources as described in the examples below:
primary Porcine Alveolar Macrophages (PAM) and primary bone marrow macrophages (BMDM) were taken from healthy SPF Bama minipigs aged 2-4 months, aseptically collected, lysed with red blood cell lysate (purchased from Biosharp), red blood cells were removed, centrifuged at low speed, the supernatant was discarded, and the cell pellet was resuspended in RPMI 1640 complete medium (purchased from Gibco) containing 10% FBS (purchased from PAN), placed at 37 ℃ and 5% CO2Culturing in an incubator.
ASFV gene II strain (ASFV CN/SC/2019) for Chinese agricultureThe virus titer of the laboratory isolate in African swine fever area of Lanzhou veterinary institute of academy of sciences is 5+107TCID50and/mL, which is the 4 th generation virus after PAM cell propagation, is subpackaged and stored in a foot and mouth disease reference laboratory (ABSL-3) of China and is reserved at the temperature of 80 ℃ below zero for later use.
ARV-825, available from seine autumn biosciences ltd, brand: belleck, cat #: s8297.
Other reagents in the experiment are common commercial reagents unless otherwise specified; the procedures in the experiments are those known in the art unless otherwise specified.
EXAMPLE 1 Effect of ARV-825 Compound on replication of African Swine fever Virus infection and Gene transcription expression
1. Changes in African Swine fever Virus infection and replication
Culture of porcine alveolar macrophages (PAM, 2X 10) in RPMI 1640+ 10% FBS medium in 96-well plates5Per well), after the experimental group treated the cells with different concentrations of ARV-825 (0.5. mu.M, 1. mu.M, 2. mu.M, 5. mu.M, 8. mu.M, 10. mu.M) for 16h, the infection control group treated the cells with DMSO (1%) for 16 h; continuously diluting ASFV CN/SC/2019 strain (MOI is 0.1) by 10 times with PBS, making 8 dilutions, repeating 8 wells for each dilution, inoculating PAM cells for culture, and adding pig red cells; place the cell plate at 37 ℃ in 5% CO2Conditioned for 3-6 days, and the erythrocyte adsorption reaction (HAD) in each cell culture well was observed daily.
The erythrocyte adsorption reaction (HAD) is based on the phenomenon that porcine red blood cells are adsorbed around mononuclear macrophages infected with african swine fever virus, thereby producing erythrocyte adsorption. The results are shown in FIG. 1, which infected HAD in control group (DMSO)50Higher value, and HAD after treatment with different concentrations of ARV-82550The value decreases, wherein the HAD is reduced when treated with 5. mu.M ARV-82550The value was reduced to half that of the control (DMSO), whereas when the dose reached 10. mu.M, there was essentially no red blood cell adsorption. The results show that the compound ARV-825 can obviously inhibit infection and replication of ASFV, and the inhibition effect is more obvious along with the increase of the concentration of the compound.
RNA transcript levels of p30 and p72
Porcine alveolar macrophages (PAM, 1X 10) were cultured in RPMI 1640+ 10% FBS medium in 48-well plates6Per well), the experimental group was infected with ASFV CN/SC/2019 strain (MOI 0.1) after treating the cells with different concentrations of ARV-825(0.5 μ M, 1 μ M, 2 μ M, 5 μ M, 8 μ M, 10 μ M) for 16h, and the control group was infected with ASFV CN/SC/2019 strain (MOI 0.1) after treating the cells with DMSO (1%) for 16 h; and (3) continuously culturing the cells infected with the ASFV CN/SC/2019 strain in the experimental group and the control group for 48h, collecting cell cultures, washing the cells once by PBS, centrifuging, and discarding the supernatant. Total RNA was extracted by Trizol method, cDNA was synthesized using the iScriptTM Reverse Transcription Supermix for RT-qPCR (Bio-Rad) kit, and the expression difference between p30 and p72RNA was detected by Q-PCR.
The Q-PCR reaction system was 20. mu.L in total volume and contained 10. mu.M of upstream and downstream primers, 90ng of cDNA, 10. mu.L of SYBR Green supermix (2X) (Bio-Rad), and sterile deionized water to 20. mu.L. The reaction conditions are as follows: at 95 ℃ for 3 min; 95 ℃, 5s, 60 ℃, 30s, 40 cycles;
wherein the sequence of the p30 primer is as follows: an upstream primer 5'-GAGGAGACGGAATCCTCAGC-3'; a downstream primer 5'-GCAAGCATATACAGCTTGGAGT-3';
the sequence of the p72 primer is as follows: an upstream primer 5'-CTGCTCATGGTATCAATCTTATCGA-3'; the downstream primer is 5 '-GATACCACAAGATCRGCCGT-3'.
The experimental results of the RNA expression levels of p30 and p72 are shown in FIG. 2, the compound ARV-825 can inhibit the RNA expression levels of p30 and p72 in the African swine fever virus gene, and the inhibition rate of the compound ARV-825 on the p30RNA expression level is nearly 50% when the dose of the compound ARV-825 is 0.5 mu M, and the inhibition rate on the p72RNA expression level is higher than 50% when the dose of the compound ARV-825 is 0.5 mu M.
Protein expression levels of p30 and p72
Porcine alveolar macrophages (PAM, 10X 10) were cultured overnight in RPMI 1640+ 10% FBS medium in 35mm dishes6) (ii) a Experimental groups treated cells with ARV-825(0.5 μ M) for 16h followed by infection with ASFV CN/SC/2019 strain (MOI 0.1), uninfected control groups treated cells with DMSO (1%) for 16 h; infection control group cells were treated with DMSO (1%) for 16h before infection with ASFV CN/SC/2019 strain (MOI ═ 0.1), and treatments were performedAfter the cells were cultured for another 48 hours, the cell culture was collected, the cells were washed once with PBS, centrifuged, and the supernatant was discarded. Extracting total protein, and detecting the expression difference of p30 and p72 proteins by using a western-blotting method.
p30 and p72 protein expression level test results as shown in FIG. 3, the expression levels of ASFV p30 and p72 proteins were increased in the infected control group (DMSO + ASFV) and the test group (ARV-825+ ASFV) compared to the uninfected control group (control group); however, the expression level of ASFV p30 and p72 protein in the experimental group (ARV-825+ ASFV) is significantly reduced compared with the infection control group (DMSO + ASFV). The result shows that the compound ARV-825 can obviously inhibit the protein expression levels of p30 and p72 in the African swine fever virus gene.
The results show that the compound ARV-825 can obviously inhibit the RNA and protein expression levels of p30 and p72 in ASFV, prevent viruses from invading host cells, and can be used for inhibiting the early infection of the ASFV.
EXAMPLE 2 Effect of ARV-825 Compound on the expression level of factors associated with inflammation of the host
Porcine alveolar macrophages (PAM, 1X 10) were cultured in RPMI 1640+ 10% FBS medium in 48-well plates6Hole/bore); experimental groups cells were treated with ARV-825(0.5 μ M) for 16h and infected with the ASFV CN/SC/2019 strain (MOI ═ 0.1); the blank control group was not treated at all; compound ARV-825 separate treatment group cells were treated with ARV-825 (0.5. mu.M) for 16 h; virus-independent infection groups cells were treated with DMSO (1%) for 16h, followed by direct infection with ASFV CN/SC/2019 strain (MOI ═ 0.1); after the cells treated as above were cultured for another 48 hours, the cell culture was collected, the cells were washed once with PBS, centrifuged, and the supernatant was discarded. After total RNA was extracted and cDNA was reverse-transcribed, differences in expression of host inflammation-associated factors were examined by Q-PCR (same as in example 1).
Wherein, the TNF-alpha primer sequence is as follows: an upstream primer 5'-GGCTGCCTTGGTTCAGATGT-3'; a downstream primer 5'-CAGGTGGGAGCAACCTACAGTT-3';
the NF-kappa B primer sequence is as follows: an upstream primer 5'-TCCAACACCGCATAAACC-3'; a downstream primer 5'-TAAAGCTCACCCGCAACG-3';
the IL-1 beta primer sequence is as follows: an upstream primer 5'-AGGGACATGGAGAAGCGATTT-3'; a downstream primer 5'-TTCTGCTTGAGAGGTGCTGATG-3';
the IL-8 primer sequence is: an upstream primer 5'-TTCCTGCTTTCTGCAGCTCTCT-3'; the downstream primer 5'-GGGTGGAAAGGGTGTGGAATG-3'.
The experimental result is shown in figure 4, compared with the blank Control group (Control), the gene expression levels of TNF-alpha, NF-kappa B, IL-1 beta, IL-8 and the like in the compound ARV-825 single treatment group (ARV-825alone) and the virus single infection group (DMSO + ASFV) are obviously reduced; compared with a blank Control group (Control), the gene expression levels of TNF-alpha, NF-kappa B, IL-1 beta, IL-8 and the like in an experimental group (ARV-825+ ASFV) are remarkably increased in a compound ARV-825alone treated group (ARV-825alone) and a virus alone infected group (DMSO + ASFV). The result shows that the compound ARV-825 can remarkably up-regulate the expression levels of genes such as TNF-alpha, NF-kappa B, IL-1 beta, IL-8 and the like after ASFV virus infection, up-regulate the transcription levels of TNF-alpha, NF-kappa B, IL-1 beta and IL-8, enhance immune response and can be used for preventing or treating African swine fever.
EXAMPLE 3 cytotoxicity of Compound ARV-825
Constructing stable in vitro cell screening system, and carrying out cytotoxicity detection on small molecule compound ARV-825 by CCK-8 method. Culture of porcine alveolar macrophages (PAM, 2X 10) in RPMI 1640+ 10% FBS medium in 96-well plates5Perwell), overnight incubation, different concentrations of ARV-825 (0.5. mu.M, 1. mu.M, 5. mu.M, 10. mu.M, 20. mu.M, 40. mu.M, 80. mu.M, 160. mu.M, 240. mu.M) were added to the wells, while blank wells (containing medium only) and control wells (containing cells and medium) were set up, 10. mu.L of CCK-8 solution was added to each well of the plate after incubation in the incubator for 16h, the plate was incubated in the incubator for 1-4h, and gentle mixing on a shaker was possible before reading the plate. And reading the absorbance at 450nm by a microplate reader, and calculating the cell survival rate.
As shown in FIG. 5, ARV-825 has low toxicity to cells, and even when the dosage reaches 20. mu.M, the cell activity still reaches more than 50%, the cytotoxicity is low, and the safety is good.
In conclusion, the compound ARV-825 disclosed by the invention has a good inhibition effect on African swine fever viruses, can enhance immune response, has low cytotoxicity and good safety, and can be used for preventing or treating African swine fever viruses.
The above embodiments are merely preferred embodiments of the present invention, and not intended to limit the scope of the invention, so that equivalent changes or modifications made based on the structure, characteristics and principles of the invention should be included in the claims of the present invention.
Claims (8)
1. The application of a compound ARV-825 in preparing a medicament for treating African swine fever is disclosed, wherein the structural formula of the compound ARV-825 is shown as the following formula (I):
（Ⅰ）。
2. the application of a compound ARV-825 in preparing a medicament for preventing African swine fever is disclosed, wherein the structural formula of the compound ARV-825 is shown as the following formula (I):
（Ⅰ）。
3. the use according to claim 1 or 2, wherein the compound ARV-825 effects treatment or prevention of african swine fever virus p30RNA expression.
4. The use of claim 1 or 2, wherein the compound ARV-825 effects treatment or prevention of african swine fever by inhibiting expression of p30 protein.
5. The use according to claim 1 or 2, wherein the compound ARV-825 effects treatment or prevention of african swine fever virus p72RNA expression.
6. The use of claim 1 or 2, wherein the compound ARV-825 effects treatment or prevention of african swine fever by inhibiting expression of p72 protein.
7. The use of claim 1 or 2, wherein the compound ARV-825 is effective in the treatment or prevention of african swine fever by promoting the expression of inflammatory factors, including TNF- α, NF- κ B, IL-1 β, IL-8.
8. The use according to claim 1 or 2, wherein the compound ARV-825 is formulated with pharmaceutically acceptable carriers and/or excipients into any one of the dosage forms of tablets, sprays, granules, capsules, oral liquids, and injections.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010684043.1A CN111588725B (en) | 2020-07-16 | 2020-07-16 | New application of compound ARV-825 in preparation of drug for preventing or treating African swine fever |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010684043.1A CN111588725B (en) | 2020-07-16 | 2020-07-16 | New application of compound ARV-825 in preparation of drug for preventing or treating African swine fever |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111588725A CN111588725A (en) | 2020-08-28 |
| CN111588725B true CN111588725B (en) | 2021-06-08 |
Family
ID=72183035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010684043.1A Active CN111588725B (en) | 2020-07-16 | 2020-07-16 | New application of compound ARV-825 in preparation of drug for preventing or treating African swine fever |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111588725B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114425053B (en) * | 2022-02-25 | 2022-10-25 | 中国农业科学院兰州兽医研究所 | Application of aprepitant compound in preparation of drugs for preventing or treating African swine fever |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201614934D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Intellectual Property (No 2) Ltd | Chemical compounds |
| GB201614939D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Ip Dev Ltd | Crystalline hydrate |
| CN110101705B (en) * | 2019-05-07 | 2022-01-14 | 河南农业大学 | Antiviral use of BET family protein inhibitors |
-
2020
- 2020-07-16 CN CN202010684043.1A patent/CN111588725B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111588725A (en) | 2020-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111588721B (en) | New application of compound ZL0580 in preparation of drugs for preventing or treating African swine fever | |
| CN113082049B (en) | New application of potassium iodide or composition containing potassium iodide in preparation of drugs for treating African swine fever | |
| CN112791084B (en) | New application of ML-60218 in preparation of drugs for treating African swine fever | |
| CN113181154B (en) | New application of EGTA in preventing or treating African swine fever | |
| WO2022188898A2 (en) | Use of cyproheptadine hydrochloride compound in preparation of drug for preventing or treating african swine fever | |
| CN111588725B (en) | New application of compound ARV-825 in preparation of drug for preventing or treating African swine fever | |
| CN111686107B (en) | New application of compound PLX51107 in preparation of drug for preventing or treating African swine fever | |
| CN113018283B (en) | Application of Metformin in inhibiting bovine viral diarrhea virus infection | |
| CN111658654A (en) | New application of compound JQ-1 in preventing or treating African swine fever | |
| CN102283838B (en) | Application of ethoxysanguinarine to pharmacy | |
| CN111686114B (en) | New application of compound I-BET-762 in preparation of drug for preventing or treating African swine fever | |
| CN113509489B (en) | New application of composition containing sodium selenite in preparation of drugs for treating African swine fever | |
| CN111973587B (en) | Application of quercetin in preparation of anti-grass carp reovirus medicine | |
| CN113274406B (en) | New application of manganese chloride or composition containing manganese chloride in preparation of drugs for treating African swine fever | |
| CN106957826B (en) | Virus inactivating agent and application thereof | |
| CN104758282B (en) | Berberine is for preparing the purposes of the medicine of viral myocarditis disease caused by treatment Coxsackie B virus 3 | |
| CN102580088A (en) | Egg yolk antibody for treating porcine circovirus disease and method for producing compound thereof | |
| CN110179785B (en) | Application of widmanone in preparation of medicine for treating or preventing hand-foot-and-mouth disease | |
| CN108272788B (en) | Puerarin is in the drug and pig feed additive for preparing the purposes in the drug for preventing and treating pig virus infection, preventing and treating pig virus infection | |
| CN102349888B (en) | Application of atractylodin alcohol in medicament preparation | |
| Duan | New Progress in Pharmacochemistry of Anti Enterovirus 71 | |
| CN1264510C (en) | Application of geldanamycin (C-3559) preparation of medicine for curing genital tract infection of condyloma accuminatum and herpes virus and on preparation of medicine for curing poliomyelitis | |
| CN114748454A (en) | Application of gossypol acetate in preparation of medicine for preventing or treating annular theileriosis | |
| CN114246858A (en) | Application of artemisinin compound in treatment and prevention of coronavirus infection | |
| CN117653633A (en) | Application of tetrandrine in preparation of medicines for preventing and treating porcine reproductive and respiratory syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |